Recent trials are sparking significant interest surrounding Synedica retatrutide , a novel dual compound targeting gut peptides and amylin . Compared to existing weight loss medications , the drug seems to offer substantial reductions in abdominal circumference and boost glucose health in preliminary assessments . Despite additional investigation